Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Carcinoma, Non-Small-Cell Lung 10Neurofibromatosis 1 9Breast Neoplasms 5Neurofibroma, Plexiform 4Lung Neoplasms 4Triple Negative Breast Neoplasms 3Neurofibrosarcoma 3Thyroid Neoplasms 2Neoplasms 2Melanoma 2Gallbladder Neoplasms 2Uveal Melanoma 1Thyroid Diseases 1Thyroid Cancer, Papillary 1Sarcoma, Kaposi 1Sarcoma 1Recurrence 1Rectal Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Optic Nerve Glioma 1Non-small Cell Lung Cancer Metastatic 1Neuroma, Acoustic 1Neurofibromatosis 2 1Neoplasm Metastasis 1Meningioma 1Liver Neoplasms 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Glioma 1

Interventions

Cyclophosphamide 82Imatinib Mesylate 81fludarabine phosphate 67fludarabine 62Whole-Body Irradiation 55Mycophenolic Acid 54Tacrolimus 42nilotinib 40Busulfan 39Dasatinib 32Cyclosporine 30Peripheral Blood Stem Cell Transplantation 28thymoglobulin 25Melphalan 25Thiotepa 24Cytarabine 24Granulocyte Colony-Stimulating Factor 23Antilymphocyte Serum 23Methotrexate 21Filgrastim 21Stem Cell Transplantation 20ponatinib 16Sirolimus 16sargramostim 14Cord Blood Stem Cell Transplantation 13Rituximab 11Cyclosporins 11Clofarabine 11venetoclax 10peginterferon alfa-2b 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × AZD 6244 × Clear all
NCT03326310 2025-12-29

Selumetinib and Azacitidine in High Risk Chronic Blood Cancers

University of Chicago

Phase 1 Recruiting
18 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡